TLDR:
– London-based biomarker development company, Inoviv, has raised an undisclosed amount in funding from Hoxton Ventures and Foresight Group.
– The funding will be used to expand commercial activities, support clinical proteomics, and accelerate the development and approval of therapeutics.
Inoviv, a London-based biomarker development company, has secured funding from Hoxton Ventures and Foresight Group. The amount of funding raised has not been disclosed. This investment will allow the company to expand its commercial activities in the pharmaceutical and biotech space, particularly in the field of clinical proteomics. Inoviv offers solutions in hybrid assays that enable the measurement of previously immeasurable biomarkers and the development of rapid standards to support quantitative workflows. The company’s panels can measure over 50 fully calibrated and validated biomarkers per sample, covering a range of analytes across different sample types. These assays can be tailored to the specific drug, disease, and mechanism of action, and are carried out in accredited laboratories. Inoviv plans to use the funding to further develop its R&D capacity and innovation to address the biomarker market and accelerate the development and approval of life-changing therapeutics. CEO Michael Dove expressed his delight at the investment, stating that it represents a significant milestone for Inoviv and will allow the company to deliver on its promise of precision biomarkers for the global pharmaceutical research community.
